User:Tkadm30/Notebook/Aripiprazole: Difference between revisions
From OpenWetWare
< User:Tkadm30 | Notebook
(Side effects) |
No edit summary |
||
| Line 12: | Line 12: | ||
===Side effects=== | ===Side effects=== | ||
* [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3666545/ Worsened hypertension control induced by aripiprazole] | * [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3666545/ Worsened hypertension control induced by aripiprazole] | ||
===See also=== | |||
* [https://en.wikipedia.org/wiki/Aripiprazole Aripiprazole] | |||
Revision as of 07:39, 26 February 2017
Functional selectivity of aripiprazole at D2 receptors
- Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways.
- Protective effect of aripiprazole against glutamate cytotoxicity in dopaminergic neurons of rat mesencephalic cultures.
- Antagonism of the adenosine A2A receptor attenuates akathisia-like behavior induced with MP-10 or aripiprazole in a novel non-human primate model.
- Repeated aripiprazole treatment causes dopamine D2 receptor up-regulation and dopamine supersensitivity in young rats.
- Unique Effects of Acute Aripiprazole Treatment on the Dopamine D2 Receptor Downstream cAMP-PKA and Akt-GSK3β Signalling Pathways in Rats
Corticostriatal glutamatergic transmission
- Presynaptic adenosine A2A receptors dampen cannabinoid CB1 receptor-mediated inhibition of corticostriatal glutamatergic transmission
- Heteromeric adenosine-CB1 activation increase functional connectivity at dopamine D2 receptors?
- Effects of Aripiprazole and Haloperidol on Fos-like Immunoreactivity in the Prefrontal Cortex
